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CASE REPoRT
CASE REPORT
A 44-year-old woman a former smoker, presented with a 
2-month history of progressive dyspnea. Computed tomography 
(CT)-scan showed diffuse alveolar opacities and micronodules 
in both lungs. Bronchoscopy was macroscopically normal, 
and bronchial biospsies were negative. Bronchioloalveolar 
lavage displayed revealed many TTF1 positive adenocarcino-
matous cells harboring an exon 19 deletion (E746-A750) of 
endothelial growth factor receptor (EGFR) gene by sequencing. 
No extrathoracic metastases were detected on brain CT-scan or 
positron emission tomography scan. A first-line chemotherapy 
with carboplatin (area under the curve = 6), paclitaxel (175 mg/
m2) and bevacizumab (15 mg/kg) every 3 weeks was started in 
December 2009. After stabilization at three cyles, the patient 
presented a pulmonary progression at six cycles. Erlotinib (150 
mg/day) was started in June 2010 (Fig. 1A). After a partial 
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FIGURE 1. CT scan evolution. A, June 2010: Alveolar opacity of the right upper lobe before erlotinib introduction. B, Major 
response after 2 months with erlotinib. C, June 2011: Mass of the right upper lobe corresponding to the SCLC transformation. 
D, Response of the right upper lobe mass with progression of the alveolar opacity, after one cycle of cisplatin and etoposide 
with erlotinib continuation. CT, computed tomography; SCLC, small-cell lung cancer.
1062 Copyright © 2012 by the International Association for the Study of Lung Cancer
Fallet et al. Journal of Thoracic Oncology  •  Volume  7, Number 6, June 2012
response was observed at 2 months (Fig. 1B), a new progres-
sion was documented on CT-scan 6 months later. Erlotinib 
was discontinued and pemetrexed (500mg/m2; d1 = d22, two 
cycles) then docetaxel (75 mg/m2; d1 = d22, one cycle) did 
not control tumor progression. In April 2011, erlotinib (150 
mg/day) was restarted but resulted in a dissociated response. 
Although peripheral alveolar opacities cleared, a proximal 
mass appeared in the right upper lobe (Fig. 1C). Fiberoptic 
bronchoscopy found a tumor stenosis of the right upper lobe 
bronchus whose biopsies revealed a small-cell lung cancer 
(SCLC); mutational analyses of the bronchial biopsy showed 
the initial exon 19 deletion (Fig. 2). Bronchial aspirate showed 
adenocarcinoma cells in which the exon 19 deletion but also 
the T790M exon 20 resistance mutation were detected (Fig. 
3). Chemotherapy by cisplatin (80mg/m2; dl = d22) and etopo-
side (100mg/m2; d1-3 = d22) (150 mg/day) was started in July 
2011 and erlotinib maintained. CT-chest revealed a decrease of 
the right upper lobe mass after one cycle. However, the patient 
secondarily died from progressive respiratory failure resulting 
from bilateral alveolar tumor progression.
DISCUSSION
EGFR mutations are associated with better response 
to tyrosine kinase inhibitors ,1 but drug resistance invariably 
emerges. The emergence of the T790M mutation accounts 
for 50% of cases.2 SCLC transformation with original EGFR 
mutation has been reported recently as a novel drug-resistance 
mechanism to EGFR inhibitors3,4.
In this case, we show that both resistance mechanisms 
were present in the same patient. Interestingly, the same 
exon 19 deletion was observed in the SCLC and in the ade-
nocarcinoma. However, the T790M was not present in the 
SCLC contingent, as if the two mechanisms were mutually 
exclusive.
Mutated SCLC seems sensitive to standard chemother-
apy for SCLC. overcoming the management issue of T790M 
clone is still under discussion, but irreversible EGFR-TKI 
may be an option.5 In conclusion, resistance mechanisms are 
heterogeneous, therefore histological and molecular follow-up 
are necessary to adapt therapy.
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FIGURE 2. Resistance as small-cell lung cancer. A, Pathological analysis of bronchial biopsy specimen showing SCLC transforma-
tion. Small cells with round or oval nuclei and sparse cytoplasm. B, Sequencing chromatogram showing an exon 19 EGFR deletion 
(black bar) in DNA extract from SCLC biopsy specimen. SCLC, small cell lung cancer; EGFR, endothelial growth factor receptor.
FIGURE 3. Resistance as T790M mutation. A, Cytological analysis of bronchial aspirate showing adenocarcinoma cells. 
Monolayered sheet of cells with uniform, round nuclei; fine nuclear chromatin; and intranuclear cytoplasmic inclusion bodies. 
B, Sequencing chromatograms of exon 20 for EGFR demonstrate the T790M mutation (c.2369C > T; p.Thr790Met) at exon 20) 
in DNA extract from adenocarcinoma cells from bronchial aspirate specimen. A red arrow indicates the mutation at nucleotide 
2369 (C > K [C + T]), which leads to substitution of Threonine (ACG) for Methionine (ATG) at position 790. EGFR, endothelial 
growth factor receptor.
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